Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2003.04.576 on July 7 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldhirsch, A.
Right arrow Articles by Senn, H.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldhirsch, A.
Right arrow Articles by Senn, H.-J.
Journal of Clinical Oncology, Vol 21, Issue 17 (September), 2003: 3357-3365
© 2003 American Society for Clinical Oncology

SPECIAL ARTICLE

Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer

Aron Goldhirsch, William C. Wood, Richard D. Gelber, Alan S. Coates, Beat Thürlimann, Hans-Jörg Senn

From the International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano; Division of Gynecologic Oncology, Kantonsspital; Zentrum für Tumordiagnostik und Prävention, Silberturm, Grossacker, St Gallen, Switzerland; European Institute of Oncology, Milan, Italy; Department of Surgery, Emory University, Atlanta, GA; Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; and The Cancer Council Australia, Sydney, New South Wales, Australia.

Address reprint requests to Aron Goldhirsch, MD, International Breast Cancer Study Group, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy; e-mail: agoldhirsch{at}sakk.ch.

This account of the highlights of the eighth St Gallen (Switzerland) meeting in 2003 emphasizes new information that has emerged during the 2 years since the seventh meeting in 2001. This article should be read in conjunction with the report of that earlier meeting. Recommendations for patient care are so critically dependent on assessment of endocrine responsiveness that the importance of high-quality steroid hormone receptor determination and standardized quantitative reporting cannot be overemphasized. The International Consensus Panel modified the risk categories so that only endocrine receptor–absent status was sufficient to reclassify an otherwise low-risk, node-negative disease into the category of average risk. Absence of steroid hormone receptors also was recognized as indicating endocrine nonresponsiveness. Some important areas highlighted at the recent meeting include: (1) recognition of the separate nature of endocrine-nonresponsive breast cancer—both invasive cancers and ductal carcinoma-in-situ; (2) improved understanding of the mechanisms of acquired endocrine resistance, which offer exciting prospects for extending the impact of successful sequential endocrine therapies; (3) presentation of high-quality evidence indicating that chemotherapy and tamoxifen should be used sequentially rather than concurrently; (4) availability of a potential alternative to tamoxifen for treatment of postmenopausal women with endocrine-responsive disease; and (5) the promise of newly defined prognostic and predictive markers.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
H. Fiegl, A. Jones, C. Hauser-Kronberger, G. Hutarew, R. Reitsamer, R. L. Jones, M. Dowsett, E. Mueller-Holzner, G. Windbichler, G. Daxenbichler, et al.
Methylated NEUROD1 Promoter is a Marker for Chemosensitivity in Breast Cancer
Clin. Cancer Res., June 1, 2008; 14(11): 3494 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Derenzini, G. Donati, G. Mazzini, L. Montanaro, M. Vici, C. Ceccarelli, D. Santini, M. Taffurelli, and D. Trere
Loss of Retinoblastoma Tumor Suppressor Protein Makes Human Breast Cancer Cells More Sensitive to Antimetabolite Exposure
Clin. Cancer Res., April 1, 2008; 14(7): 2199 - 2209.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard
Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group
J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. E. Cazzaniga, G. Mustacchi, P. Pronzato, A. De Matteis, F. Di Costanzo, I. Floriani, and On behalf of the NORA Study Group
Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study
Ann. Onc., December 1, 2007; 18(12): 1976 - 1980.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Meslin, R. Conforti, C. Mazouni, N. Morel, G. Tomasic, F. Drusch, M. Yacoub, J. C. Sabourin, J. Grassi, S. Delaloge, et al.
Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer
Ann. Onc., November 1, 2007; 18(11): 1793 - 1798.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Thomassen, Q. Tan, F. Eiriksdottir, M. Bak, S. Cold, and T. A. Kruse
Comparison of Gene Sets for Expression Profiling: Prediction of Metastasis from Low-Malignant Breast Cancer
Clin. Cancer Res., September 15, 2007; 13(18): 5355 - 5360.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R Conforti, T Boulet, G Tomasic, E Taranchon, R Arriagada, M Spielmann, M Ducourtieux, J. Soria, T Tursz, S Delaloge, et al.
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
Ann. Onc., September 1, 2007; 18(9): 1477 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Mita, Z. Zhang, Y. Ando, T. Toyama, M. Hamaguchi, S. Kobayashi, S.-i. Hayashi, Y. Fujii, H. Iwase, and H. Yamashita
Prognostic Significance of Insulin-like Growth Factor Binding Protein (IGFBP)-4 and IGFBP-5 Expression in Breast Cancer
Jpn. J. Clin. Oncol., August 3, 2007; (2007) hym066v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
L. M. Davis, C. Harris, L. Tang, P. Doherty, P. Hraber, Y. Sakai, T. Bocklage, K. Doeden, B. Hall, J. Alsobrook, et al.
Amplification Patterns of Three Genomic Regions Predict Distant Recurrence in Breast Carcinoma
J. Mol. Diagn., July 1, 2007; 9(3): 327 - 336.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Griggs, E. Culakova, M. E.S. Sorbero, M. S. Poniewierski, D. A. Wolff, J. Crawford, D. C. Dale, and G. H. Lyman
Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens
J. Clin. Oncol., June 20, 2007; 25(18): 2522 - 2527.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. H. Ahn, B. H. Son, S. W. Kim, S. I. Kim, J. Jeong, S.-S. Ko, and W. Han
Poor Outcome of Hormone Receptor-Positive Breast Cancer at Very Young Age Is Due to Tamoxifen Resistance: Nationwide Survival Data in Korea--A Report From the Korean Breast Cancer Society
J. Clin. Oncol., June 10, 2007; 25(17): 2360 - 2368.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Desmedt, F. Piette, S. Loi, Y. Wang, F. Lallemand, B. Haibe-Kains, G. Viale, M. Delorenzi, Y. Zhang, M. S. d'Assignies, et al.
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series
Clin. Cancer Res., June 1, 2007; 13(11): 3207 - 3214.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Paik
Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen
Oncologist, June 1, 2007; 12(6): 631 - 635.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Otsuki, S.-i. Shimizu, K. Suwa, M. Yoshida, M. Kanzaki, and H. Kobayashi
Which is the Better Pathological Prognostic Factor, the Nottingham Histological Grade or the Japanese Nuclear Grade? A Large Scale Study with a Long-term Follow-up
Jpn. J. Clin. Oncol., April 1, 2007; 37(4): 266 - 274.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Sarp, G. Fioretta, H. M. Verkooijen, G. Vlastos, E. Rapiti, H. Schubert, A.-P. Sappino, and C. Bouchardy
Tumor Location of the Lower-Inner Quadrant Is Associated with an Impaired Survival for Women With Early-Stage Breast Cancer
Ann. Surg. Oncol., March 1, 2007; 14(3): 1031 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Climent, P. Dimitrow, J. Fridlyand, J. Palacios, R. Siebert, D. G. Albertson, J. W. Gray, D. Pinkel, A. Lluch, and J. A. Martinez-Climent
Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer
Cancer Res., January 15, 2007; 67(2): 818 - 826.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
Y. Sun, S. Goodison, J. Li, L. Liu, and W. Farmerie
Improved breast cancer prognosis through the combination of clinical and genetic markers
Bioinformatics, January 1, 2007; 23(1): 30 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Lacroix
Significance, detection and markers of disseminated breast cancer cells
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A Goldhirsch, A. Coates, R. Gelber, J. Glick, B Thurlimann, H-J Senn, and On behalf of the St Gallen Expert Panel Members
First--select the target: better choice of adjuvant treatments for breast cancer patients
Ann. Onc., December 1, 2006; 17(12): 1772 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. M. Regan, G. Viale, M. G. Mastropasqua, E. Maiorano, R. Golouh, A. Carbone, B. Brown, M. Suurkula, G. Langman, L. Mazzucchelli, et al.
Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays.
J Natl Cancer Inst, November 1, 2006; 98(21): 1571 - 1581.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. R. Hess, K. Anderson, W. F. Symmans, V. Valero, N. Ibrahim, J. A. Mejia, D. Booser, R. L. Theriault, A. U. Buzdar, P. J. Dempsey, et al.
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
J. Clin. Oncol., September 10, 2006; 24(26): 4236 - 4244.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Buyse, S. Loi, L. van't Veer, G. Viale, M. Delorenzi, A. M. Glas, M. Saghatchian d'Assignies, J. Bergh, R. Lidereau, P. Ellis, et al.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
J Natl Cancer Inst, September 6, 2006; 98(17): 1183 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Cazzaniga, G Mustacchi, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group
Adjuvant systemic treatment of early breast cancer: the NORA study
Ann. Onc., September 1, 2006; 17(9): 1386 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Wardley
Capecitabine: Expanding Options for the Treatment of Patients with Early or Locally Advanced Breast Cancer
Oncologist, September 1, 2006; 11(suppl_1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Paik, G. Tang, S. Shak, C. Kim, J. Baker, W. Kim, M. Cronin, F. L. Baehner, D. Watson, J. Bryant, et al.
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer
J. Clin. Oncol., August 10, 2006; 24(23): 3726 - 3734.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Z. Ring, R. S. Seitz, R. Beck, W. J. Shasteen, S. M. Tarr, M. C.U. Cheang, B. J. Yoder, G. T. Budd, T. O. Nielsen, D. G. Hicks, et al.
Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor-Positive Breast Cancer
J. Clin. Oncol., July 1, 2006; 24(19): 3039 - 3047.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Toyama, Z. Zhang, H. Iwase, H. Yamashita, Y. Ando, M. Hamaguchi, M. Mizutani, N. Kondo, T. Fujita, Y. Fujii, et al.
Low Expression of the Snail Gene is a Good Prognostic Factor in Node-Negative Invasive Ductal Carcinomas
Jpn. J. Clin. Oncol., June 1, 2006; 36(6): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Nilsson, and J. Bergh
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
J. Clin. Oncol., June 1, 2006; 24(16): 2428 - 2436.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Foekens, D. Atkins, Y. Zhang, F. C.G.J. Sweep, N. Harbeck, A. Paradiso, T. Cufer, A. M. Sieuwerts, D. Talantov, P. N. Span, et al.
Multicenter Validation of a Gene Expression-Based Prognostic Signature in Lymph Node-Negative Primary Breast Cancer
J. Clin. Oncol., April 10, 2006; 24(11): 1665 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Wulfing, J. Borchard, H. Buerger, S. Heidl, K. S. Zanker, L. Kiesel, and B. Brandt
HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients.
Clin. Cancer Res., March 15, 2006; 12(6): 1715 - 1720.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. H. Roukos, E. Paraskevaidis, and A. M. Kappas
Surgery in the Era of Gene Expression Profiling-Based Prediction and Individualized, Neoadjuvant Breast Cancer Therapy: The Beginning of the End?
Ann. Surg. Oncol., March 1, 2006; 13(3): 433 - 435.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J S Reis-Filho, C Westbury, and J-Y Pierga
The impact of expression profiling on prognostic and predictive testing in breast cancer.
J. Clin. Pathol., March 1, 2006; 59(3): 225 - 231.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Burdette-Radoux and H. B. Muss
Adjuvant chemotherapy in the elderly: whom to treat, what regimen?
Oncologist, March 1, 2006; 11(3): 234 - 242.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Honma, K. Takubo, M. Sawabe, T. Arai, F. Akiyama, G. Sakamoto, T. Utsumi, N. Yoshimura, and N. Harada
Estrogen-Metabolizing Enzymes in Breast Cancers from Women over the Age of 80 Years
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 607 - 613.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Oncologist, February 1, 2006; 11(2): 111 - 125.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
International Breast Cancer Study Group
Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93
J. Clin. Oncol., January 20, 2006; 24(3): 337 - 344.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Isidoro, E. Casado, A. Redondo, P. Acebo, E. Espinosa, A. M. Alonso, P. Cejas, D. Hardisson, J. A. Fresno Vara, C. Belda-Iniesta, et al.
Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis
Carcinogenesis, December 1, 2005; 26(12): 2095 - 2104.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Ann. Onc., November 1, 2005; 16(11): 1723 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N. Engl. J. Med., October 20, 2005; 353(16): 1659 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Talcott
Rebalancing Ratios and Improving Impressions: Later Thoughts From the Prostate Cancer Prevention Trial Investigators
J. Clin. Oncol., October 20, 2005; 23(30): 7388 - 7390.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
Ann. Onc., October 1, 2005; 16(10): 1569 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Katz
Does Neoadjuvant/Adjuvant Chemotherapy Change the Natural History of Classic Invasive Lobular Carcinoma?
J. Clin. Oncol., September 20, 2005; 23(27): 6796 - 6796.
[Full Text] [PDF]

Home page
 JCOHome page
J. P.A. Baak, P. J. van Diest, F. J. Voorhorst, E. van der Wall, L. V.A.M. Beex, J. B. Vermorken, and E. A.M. Janssen
Prospective Multicenter Validation of the Independent Prognostic Value of the Mitotic Activity Index in Lymph Node-Negative Breast Cancer Patients Younger Than 55 Years
J. Clin. Oncol., September 1, 2005; 23(25): 5993 - 6001.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. D. Ryan, D. B. Kopans, and D. C. Sgroi
Case 24-2005 - A 58-Year-Old Woman with Early-Stage Estrogen-Receptor-Positive Breast Cancer
N. Engl. J. Med., August 11, 2005; 353(6): 617 - 622.
[Full Text] [PDF]

Home page
 JCOHome page
G. B. Mann, V. D. Fahey, F. Feleppa, and M. R. Buchanan
Reliance on Hormone Receptor Assays of Surgical Specimens May Compromise Outcome in Patients With Breast Cancer
J. Clin. Oncol., August 1, 2005; 23(22): 5148 - 5154.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Punglia, K. M. Kuntz, E. P. Winer, J. C. Weeks, and H. J. Burstein
Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis
J. Clin. Oncol., August 1, 2005; 23(22): 5178 - 5187.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Boccardo, A. Rubagotti, M. Puntoni, P. Guglielmini, D. Amoroso, A. Fini, G. Paladini, M. Mesiti, D. Romeo, M. Rinaldini, et al.
Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial
J. Clin. Oncol., August 1, 2005; 23(22): 5138 - 5147.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Colleoni, S. Gelber, and A. Goldhirsch
Treatment of advanced breast cancer: the good, the bad and the ugly
Ann. Onc., August 1, 2005; 16(8): 1219 - 1221.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Brunello, U. Basso, C. Pogliani, A. Jirillo, C. Ghiotto, H. Koussis, F. Lumachi, M. Iacobone, L. Vamvakas, and S. Monfardini
Adjuvant chemotherapy for elderly patients (>=70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients
Ann. Onc., August 1, 2005; 16(8): 1276 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. F. Reid, L. Lusa, L. De Cecco, D. Coradini, S. Veneroni, M. G. Daidone, M. Gariboldi, and M. A. Pierotti
Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome
J Natl Cancer Inst, June 15, 2005; 97(12): 927 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Rouzier, R. Rajan, P. Wagner, K. R. Hess, D. L. Gold, J. Stec, M. Ayers, J. S. Ross, P. Zhang, T. A. Buchholz, et al.
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
PNAS, June 7, 2005; 102(23): 8315 - 8320.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Martin, T. Pienkowski, J. Mackey, M. Pawlicki, J.-P. Guastalla, C. Weaver, E. Tomiak, T. Al-Tweigeri, L. Chap, E. Juhos, et al.
Adjuvant Docetaxel for Node-Positive Breast Cancer
N. Engl. J. Med., June 2, 2005; 352(22): 2302 - 2313.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S O Wurtz, A-S Schrohl, N M. Sorensen, U Lademann, I J Christensen, H Mouridsen, and N Brunner
Tissue inhibitor of metalloproteinases-1 in breast cancer
Endocr. Relat. Cancer, June 1, 2005; 12(2): 215 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. W.M. Martens, I. Nimmrich, T. Koenig, M. P. Look, N. Harbeck, F. Model, A. Kluth, J. Bolt-de Vries, A. M. Sieuwerts, H. Portengen, et al.
Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer
Cancer Res., May 15, 2005; 65(10): 4101 - 4117.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Andre, A. Khalil, K. Slimane, C. Massard, M. C. Mathieu, S. Vignot, H. Assi, S. Delaloge, and M. Spielmann
Mitotic Index and Benefit of Adjuvant Anthracycline-Based Chemotherapy in Patients With Early Breast Cancer
J. Clin. Oncol., May 1, 2005; 23(13): 2996 - 3000.
[Abstract] [Full Text] [PDF]